Clinical trials: Locally Advanced Carcinoma
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non Small Cell Lung Cancer
A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer
The purpose of this study is to compare two different approaches to treating non-small cell lung cancer (NSCLC) in East Asian never-smoker participants.
- Trial name
- NCT01017874
- Testing
- Pemetrexed, Cisplatin, Gefitinib
- Where
- 12 sites in Hong Kong, Singapore and 3 more
- Volunteers
- 236 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC)
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
The purpose was to evaluate the efficacy and safety of the combination of capmatinib with pembrolizumab compared to pembrolizumab alone as first-line treatment for subjects with locally advanced or metastatic NSCLC who have PD-L1…
- Trial name
- NCT04139317
- Testing
- Capmatinib, Pembrolizumab
- Where
- 36 sites in Australia, Belgium and 14 more
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Gallbladder Adenocarcinoma, Gallbladder Adenocarcinoma With Squamous Metaplasia, Hilar Cholangiocarcinoma
- Trial name
- NCT01093222
- Testing
- Erlotinib Hydrochloride, Sorafenib Tosylate
- Where
- 141 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
A Study Of PF-06664178 In Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06664178 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02122146
- Testing
- PF-06664178
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Pfizer
Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva
This phase II trial studies how well radiation therapy works when given with gemcitabine hydrochloride and cisplatin work in treating patients with squamous cell cancer of the vulva that has spread from where it started to nearby…
- Conditions
- Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7
- Trial name
- NCT01595061
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- 193 sites in United States
- Volunteers
- 57 people
- Sponsor
- Gynecologic Oncology Group
Squamous Cell Carcinoma of the Head and Neck
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
This is a Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT05459129
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Carcinoma, Renal Cell
Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
This was a randomized, open-label, parallel group Phase III non inferiority study to evaluate the efficacy and safety of pazopanib compared with sunitinib in subjects with advanced renal cell carcinoma (RCC) who had not received…
- Trial name
- COMPARZ (NCT00720941)
- Testing
- Pazopanib, Sunitinib
- Where
- 227 sites in United States, Australia and 12 more
- Volunteers
- 1,110 people
- Sponsor
- Novartis Pharmaceuticals
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
This phase II trial studies the best dose and side effects of sorafenib tosylate and nivolumab in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to nearby tissues or lymph nodes…
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03439891
- Testing
- Nivolumab, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Robin Kate Kelley
Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma
Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck
The purpose of the Phase I part of this research study is to determine the safest and most effective dose of Abraxane when given in combination with carboplatin and Erbitux during radiation therapy for head and neck cancer.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Basaloid Squamous Cell Carcinoma, Undifferentiated Carcinoma, Adenosquamous Cell Carcinoma
- Trial name
- NCT00570674
- Testing
- Abraxane, Erbitux, Carboplatin
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Head and Neck Cancer
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00503997
- Testing
- oxaliplatin, pemetrexed disodium
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
This phase II trial studies how well cabozantinib works in treating patients with adrenal cortex cancer that has spread to nearby tissue, lymph nodes (locally advanced), or other places in the body (metastatic), and cannot be…
- Conditions
- Metastatic Carcinoma in the Adrenal Cortex, Stage III Adrenal Cortex Carcinoma AJCC v8, Stage IV Adrenal Cortex Carcinoma AJCC v8, Unresectable Adrenal Cortex Carcinoma
- Trial name
- NCT03370718
- Testing
- Cabozantinib, Pharmacogenomic Study, Pharmacokinetic Study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with…
- Trial name
- NCT00520676
- Testing
- pemetrexed, docetaxel, carboplatin
- Where
- 20 sites in Australia, Brazil and 4 more
- Volunteers
- 260 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal…
- Trial name
- NCT04267120
- Testing
- Lenvatinib, Pembrolizumab, Research blood collection
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Non-Small-Cell Lung
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre study assessing the efficacy and safety of durvalumab compared with placebo, as consolidation therapy in patients with locally advanced, unresectable…
- Trial name
- PACIFIC-5 (NCT03706690)
- Testing
- Durvalumab
- Where
- 87 sites in China, Hong Kong and 8 more
- Volunteers
- 407 people
- Sponsor
- AstraZeneca
Solid Tumor, Cancer
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally…
- Conditions
- Solid Tumor, Cancer, Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT02705105
- Testing
- Mogamulizumab + Nivolumab
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- Kyowa Kirin, Inc.
Non-small Cell Lung Cancer
Navelbine And Radiotherapy in Locally Advanced Lung Cancer
This study is an open label randomized multi-centre phase II trial in patients with inoperable locally advanced stage IIB-IIIB Non Small Cell Lung Cancer who fulfils the general criteria for curatively intended irradiation.
- Trial name
- NARLAL (NCT00887783)
- Testing
- Navelbine, 66 Gy/33F, 60 Gy/30F
- Where
- 6 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Odense University Hospital
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
A Phase Ib/II, open label, multi-center, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally…
- Trial name
- NCT03281369
- Testing
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 219 people
- Sponsor
- Hoffmann-La Roche
Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
This phase I/II trial studies the best dose of pembrolizumab and binimetinib and how well it works when given together with pembrolizumab in treating patients with triple negative breast cancer that has spread to other parts of…
- Conditions
- Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT03106415
- Testing
- Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mayo Clinic